SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/A24140935F5610EE71D97059F2E075148E85B201F7C40E1C3CE7D4284DF237FDA9E3C6438137B6B92722FBA917BBE3E8>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/A24140935F5610EE71D97059F2E075148E85B201F7C40E1C3CE7D4284DF237FDA9E3C6438137B6B92722FBA917BBE3E8
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/A24140935F5610EE71D97059F2E075148E85B201F7C40E1C3CE7D4284DF237FDA9E3C6438137B6B92722FBA917BBE3E8
http://www.w3.org/2000/01/rdf-schema#comment
"FECD has the potential to be a model for treating many trinucleotide repeat diseases and targeting the TCF4 expansion with ASOs represents a promising therapeutic strategy to prevent and treat FECD."
xsd:string
http://purl.uniprot.org/uniprot/#_48CEC47908FAA9ACE0B700C4D0452E94A85F58B5E985B00D71BCA17B2A39451055461A7E09603E811CA40EE78EA9F525
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/A24140935F5610EE71D97059F2E075148E85B201F7C40E1C3CE7D4284DF237FDA9E3C6438137B6B92722FBA917BBE3E8
http://purl.uniprot.org/uniprot/A0A0A0MTL7
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/A24140935F5610EE71D97059F2E075148E85B201F7C40E1C3CE7D4284DF237FDA9E3C6438137B6B92722FBA917BBE3E8
http://purl.uniprot.org/uniprot/#_A0A0A0MTL7-mappedCitation-29325021
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/A24140935F5610EE71D97059F2E075148E85B201F7C40E1C3CE7D4284DF237FDA9E3C6438137B6B92722FBA917BBE3E8